Nuveen Asset Management LLC Has $35.87 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Nuveen Asset Management LLC grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,807,420 shares of the biopharmaceutical company's stock after purchasing an additional 159,139 shares during the period. Nuveen Asset Management LLC owned about 1.27% of Amicus Therapeutics worth $35,866,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. grew its position in shares of Amicus Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock worth $275,619,000 after purchasing an additional 458,143 shares in the last quarter. Wellington Management Group LLP grew its position in shares of Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock worth $268,112,000 after purchasing an additional 4,497,950 shares in the last quarter. Northern Trust Corp grew its position in shares of Amicus Therapeutics by 5.9% during the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock worth $31,761,000 after purchasing an additional 187,652 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Amicus Therapeutics by 3.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company's stock worth $30,779,000 after acquiring an additional 107,348 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Amicus Therapeutics during the 4th quarter worth approximately $29,033,000.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on FOLD shares. UBS Group increased their price target on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Wall Street Zen lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Wells Fargo & Company reduced their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. The Goldman Sachs Group reduced their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

NASDAQ:FOLD traded down $0.04 on Friday, hitting $6.22. The company had a trading volume of 2,822,292 shares, compared to its average volume of 2,841,418. The stock has a market capitalization of $1.92 billion, a price-to-earnings ratio of -34.56, a PEG ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The firm has a 50 day moving average of $7.11 and a two-hundred day moving average of $8.74. Amicus Therapeutics, Inc. has a 52 week low of $5.81 and a 52 week high of $12.65.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.